Malaysian biotech CytoMed Therapeutics (GDTC) has filed for a projected $15M archetypal nationalist offering.
The institution hopes to database its shares connected Nasdaq nether the awesome GDTC. The Benchmark Co. and Axiom Capital Management are serving arsenic pb bookrunners.
Incorporated successful Singapore, CytoMed conducts astir of its operations successful Malaysia. The institution has been processing cell-based immunotherapies for treating cancer. It hopes to usage proceeds from the IPO to beforehand 2 pb cause candidates into Phase 1 testing.
A pre-clinical signifier company, CytoMed is presently operating successful the red. For the six-month play ended June 30, CytoMed reported a nett nonaccomplishment of $1M and nary revenue.
For much IPO News, cheque retired SA's IPO News page.